{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:10:07Z","timestamp":1749895807894,"version":"3.41.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01500-4","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:12:40Z","timestamp":1747890760000},"page":"835-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on \u201cExamining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria\u201d"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-6133","authenticated-orcid":false,"given":"Benjamin","family":"Farrar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gladwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-025-01472-5","author":"J Donoghue","year":"2025","unstructured":"Donoghue J, Youngs M, Reeve A, Vydyula K, Kunst N, Trikha R, et al. Examining consistency across NICE single technology appraisals: a review of appraisals for paroxysmal nocturnal haemoglobinuria. Pharmacoeconomics. 2025. https:\/\/doi.org\/10.1007\/s40273-025-01472-5.","journal-title":"Pharmacoeconomics"},{"key":"1500_CR2","unstructured":"National Institute for Health and Care Excellence. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. 2022. https:\/\/www.nice.org.uk\/guidance\/ta778. Accessed Mar 2025."},{"key":"1500_CR3","unstructured":"National Institute for Health and Care Excellence. Iptacopan for treating paroxysmal nocturnal haemoglobinuria. 2024. https:\/\/www.nice.org.uk\/guidance\/ta1000. Accessed Mar 2025."},{"key":"1500_CR4","unstructured":"National Institute for Health and Care Excellence. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. 2024. https:\/\/www.nice.org.uk\/guidance\/ta1010. Accessed Mar 2025."},{"key":"1500_CR5","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed Feb 2025."},{"key":"1500_CR6","unstructured":"National Institute for Health and Care Excellence. MTA process timeline. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/process\/mta-timeline. Accessed Feb 2025."},{"issue":"5","key":"1500_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s41669-024-00490-x","volume":"8","author":"D Lee","year":"2024","unstructured":"Lee D, Burns D, Wilson E. NICE\u2019s pathways pilot: pursuing good decision making in difficult circumstances. Pharmacoecon Open. 2024;8(5):645\u20139. https:\/\/doi.org\/10.1007\/s41669-024-00490-x.","journal-title":"Pharmacoecon Open."},{"key":"1500_CR8","unstructured":"National Institute for Health and Care Excellence. Guide to the technology appraisal and highly specialised technologies appeal process. 4. Making an appeal. NICE process and methods [PMG41]. 2023. https:\/\/www.nice.org.uk\/process\/pmg41\/chapter\/making-an-appeal. Accessed Feb 2025."},{"key":"1500_CR9","unstructured":"NICE Decision Support Unit. Full list of technical support documents (TSDs). 2025. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list. Accessed Mar 2025."},{"issue":"12","key":"1500_CR10","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1016\/j.jval.2023.09.2045","volume":"26","author":"M Ivkovic","year":"2023","unstructured":"Ivkovic M, Crawford E, Gorst-Rasmussen A, Jen M. HTA362 being specific about analysis prespecification: challenges and opportunities in the context of EU HTA. Value Health. 2023;26(12):S390.","journal-title":"Value Health"},{"issue":"2","key":"1500_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hec.4730030206","volume":"3","author":"A Briggs","year":"1994","unstructured":"Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95\u2013104. https:\/\/doi.org\/10.1002\/hec.4730030206.","journal-title":"Health Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01500-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01500-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:48:38Z","timestamp":1749894518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01500-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01500-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"3 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Benjamin Farrar, Daniel Gladwell and Matthew Woods are employees of Lumanity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no data associated with this letter.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}